Skip to content

Imbruvica

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    AbbVie files patent lawsuit against BeiGene over Brukinsa

    Lawsuit filed

    AbbVie’s Pharmacyclics unit filed a lawsuit against BeiGene in federal court in Delaware, alleging that BeiGene’s Brukinsa infringes a patent on AbbVie’s Imbruvica. AbbVie sought a declaratory judgment of infringement and damages; BeiGene said it would vigorously defend against the allegations.

    Company response

    • Denial — BeiGene

      BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.

    Source excerpt

    • Through its complaint, filed the same day in federal court in Delaware, US, AbbVie is seeking a declaratory judgment of infringement, as well as damages.
    • AbbVie’s Pharmacyclics unit has filed a lawsuit against BeiGene, alleging that the biotech’s Brukinsa (zanubrutinib) infringes a patent on its own blood cancer drug Imbruvica (ibrutinib).
    • BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.